UPMC begins sharing biometric screening results for its new employees with consent
Oct. 2023Important Notices
New employees complete a biometric screening as part of UPMC’s hiring process. During the biometric screening they have clinically appropriate titers and total cholesterol, triglyceride, and glucose levels drawn.
Effective September 2023, new UPMC employees may consent to share all preplacement-related lab work with their PCP. PCPs will receive results from Quest Quanum based on their preferred method on file with Quest. Providers without a method on file will receive results via fax.
Employees may consult with their PCP office regarding these test results. Additionally, UPMC Employee Health will offer any recommended vaccinations, health coaching, and other wellness-related services.
Effective September 2023, new UPMC employees may consent to share all preplacement-related lab work with their PCP. PCPs will receive results from Quest Quanum based on their preferred method on file with Quest. Providers without a method on file will receive results via fax.
Employees may consult with their PCP office regarding these test results. Additionally, UPMC Employee Health will offer any recommended vaccinations, health coaching, and other wellness-related services.
Recent Announcements
Voluntary nationwide recall: Atorvastatin (Alkem – October)
Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.Nov. 2025Pharmacy Updates
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates